534 related articles for article (PubMed ID: 31719050)
21. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
[TBL] [Abstract][Full Text] [Related]
22. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
[TBL] [Abstract][Full Text] [Related]
23. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
24. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
25. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.
Santos FA; Reis RM; Barroti LC; Pereira AAL; Matsushita MM; de Carvalho AC; Datorre JG; Berardinelli GN; Araujo RLC
J Gastrointest Cancer; 2024 Mar; 55(1):344-354. PubMed ID: 37608030
[TBL] [Abstract][Full Text] [Related]
26. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
[TBL] [Abstract][Full Text] [Related]
27. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
[TBL] [Abstract][Full Text] [Related]
28. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.
Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI
Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
Lin JK; Lin PC; Lin CH; Jiang JK; Yang SH; Liang WY; Chen WS; Chang SC
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S680-6. PubMed ID: 24841357
[TBL] [Abstract][Full Text] [Related]
30. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Kleist B; Meurer T; Poetsch M
Tumour Biol; 2017 Mar; 39(3):1010428317692246. PubMed ID: 28345467
[TBL] [Abstract][Full Text] [Related]
32. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
33. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
[TBL] [Abstract][Full Text] [Related]
34. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
35. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR; Vakiani E; Sylvester BE; Scott SN; McDermott G; Shah RH; Kania K; Viale A; Oschwald DM; Vacic V; Emde AK; Cercek A; Yaeger R; Kemeny NE; Saltz LB; Shia J; D'Angelica MI; Weiser MR; Solit DB; Berger MF
Genome Biol; 2014 Aug; 15(8):454. PubMed ID: 25164765
[TBL] [Abstract][Full Text] [Related]
36. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
[TBL] [Abstract][Full Text] [Related]
37. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
39. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
40. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]